clinical trial · NCT07365332
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial HypertensionIKT-001Placebo
brief summary
This is an adaptive, 2-part, randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of IKT-001 in adult participants with WHO Group 1 PAH.
started
Mar 1, 2026
primary completion
Jun 1, 2029
completion
Dec 1, 2029
last updated
Jan 27, 2026
official title
An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension (PAH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol